anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Depression is a serious medical illness that is often difficult to diagnose and treat. It occurs in people of all ages, but is often overlooked in older adults. Depression frequently co-occurs with other serious illnesses, and may be mistaken by both patients and health care givers as a normal consequence of the illness. However, these misconceptions toward depression contribute to the underdiagnosis and undertreatment of depressive disorders in older people. In turn, depression may hinder a patient's recovery from an illness. This study will evaluate the effectiveness of memantine in improving rehabilitation outcomes and preventing major depressive disorder in older adults who have been admitted to a rehabilitation hospital for a hip fracture or a cardiopulmonary condition.

This double-blind study will last for 12 months. Participants will be randomly assigned to receive either placebo or memantine, which is a drug that is often used to treat Alzheimer's disease. Both memantine and placebo will be administered to participants for 12 weeks. All participants will be followed for an additional 40 weeks. Outcome measurements will include participants' depressive symptoms, motivation, and learned helplessness. In addition, medication side effects, functional outcome, and incidence of major depressive disorder will be measured. All measurements will be taken at Week 12 and Month 12.
NEW MATERIAL:A compound expressed by the formula. USE:A medicine, capable of exhibiting inhibitory action on enzymes and having action on deterioration in activity thereof by linking to intracorporeal enzyme protein. PREPARATION:A plant, e.g. betel palm tree, is extracted with aqueous acetone and the acetone is distilled away to filter off deposited brown precipitates. The resultant filtrate is then distributed with ethyl acetate, and the aqueous layer is mixed with Celite 545 and air-dried. The resultant dried mixture is filled in a column and eluted with acetone. After distilling away the solvent in the eluate, the resultant residue is eluted with water and then methanol added thereto using Sephadex LH-20 to afford the aimed compound which is yellowish brown powder and expressed by the formula.
It is not clearly known whether the beneficial effects observed in epilepsy are due to direct inhibition of carbonic anhydrase in the central nervous system or whether they are due to the slight degree of acidosis produced by the divided dosage. The best results to date have been seen in petit mal in pediatric patients. Good results, however, have been seen in patients, both pediatric patients and adult, in other types of seizures such as grand mal, mixed seizure patterns, myoclonic jerk patterns, etc. The suggested total daily dose is 8 to 30 mg per kg in divided doses. Although some patients respond to a low dose, the optimum range appears to be from 375 to 1000 mg daily. However, some investigators feel that daily doses in excess of 1 g do not produce any better results than a 1 g dose. When acetazolamide is given in combination with other anticonvulsants, it is suggested that the starting dose should be 250 mg once daily in addition to the existing medications. This can be increased to levels as indicated above.

The change from other medications to acetazolamide should be gradual and in accordance with usual practice in epilepsy therapy.
The invention discloses defatted rice bran mask paper and a preparation method thereof. The preparation method comprises the steps of adding an excipient, a wetting agent, water and the like by using defatted rice bran as a main material, then carrying out high-pressure homogenization and emulsification, forming by using a mould, and drying to obtain the defatted rice bran mask paper, wherein the raw materials comprise 5-10 percent by weight of defatted rice bran, 4.5-9 percent by weight of excipient, 0.3-3 percent by weight of wetting agent and the balance of water. The invention provides mask paper which is convenient to use and is environment-friendly and degradable, and an effective path is provided for comprehensive utilization of rice bran resources. The mask paper can be taken out from a packaging bag and then attached to the face for use, is convenient to use, simple in manufacture process, low in cost and degradable, and is an environment-friendly product. The defatted rice bran mask paper is added with the wetting agent besides skin nutritional protection agents such as phytosterol, oryzanol, vitamin E and phytic acid contained in rice bran so as to play a role of replenishing water to the skin. Meanwhile, the invention provides a preparation method for producing the defatted rice bran mask paper, which is simple in production process and low in cost.
BACKGROUND: The study determined the proportion of patients with pancreatic adenocarcinoma (PDAC) who had margin-positive disease and no other adverse pathologic findings (APF) using institutional and administrative datasets.
METHODS: Patients with clinical stage I or II PDAC in the National Cancer Database (NCDB 2010-2020) and those who underwent pancreatectomy at the authors' institution (2010-2021) were identified. Isolated margin positivity (IMP) was defined as a positive surgical margin with no APF (negative nodes, no lymphovascular/perineural invasion).
RESULTS: The study included 225 patients from the authors' institution and 23,598 patients from the NCDB. The margin-positive rates were 21.8% and 20.3%, and the IMP rates were 0.4% and 0.5%, respectively. In the institutional cohort, 68.4% of the patients had recurrence, and most of the patients (65.6%) had distant recurrences. The median recurrence-free survival (RFS) was 63.3 months for no APF, not reached for IMP, 14.8 months for negative margins & 1 APF, 20.3 months for positive margins & 2 APFs, and 12.9 months with all APF positive. The patients in the NCDB with IMP had a lower median OS than the patients with no APF (20.5 vs 390 months), but a higher median OS than those with margin positivity plus 1 APF (20.5 vs 18.0 months) or all those with APF positivity (20.5 vs 15.4 months). Based on institutional rates of IMP, any margin positivity, neck margin positivity (NMP), and no APF, the fraction of patients who might benefit from neck margin revision was 1 in 100,000, and those likely to benefit from any margin revision was 1 in 18,500. In the NCDB, those estimated to derive potential benefit from margin revision was 1 in 25,000.
CONCLUSIONS: Isolated margin positivity in resected PDAC is rare, and most patients experience distant recurrence. Revision of IMP appears unlikely to confer benefit to most patients.
Liver fibrosis is a common pathological feature of most chronic liver diseases with no effective drugs available. Phosphodiesterase 1 (PDE1), a subfamily of the PDE super enzyme, might work as a potent target for liver fibrosis by regulating the concentration of cAMP and cGMP. However, there are few PDE1 selective inhibitors, and none has been investigated for liver fibrosis treatment yet. Herein, compound AG-205/1186117 with the dihydropyrimidine scaffold was selected as the hit by virtual screening. A hit-to-lead structural modification led to a series of dihydropyrimidine derivatives. Lead 13h exhibited the IC50 of 10 nM against PDE1, high selectivity over other PDEs, as well as good safety properties. Administration of 13h exerted significant anti-liver fibrotic effects in bile duct ligation-induced fibrosis rats, which also prevented TGF-β-induced myofibroblast differentiation in vitro, confirming that PDE1 could work as a potential target for liver fibrosis.
Aspects of the present invention provide a supply chain system to get to a just-in-time inventory. Aspects of the invention generate a suggested reorder quantity by comparing the item's reorder point (quantity at which to reorder the item from the vendor) to the dynamic inventory level for the item. The dynamic inventory level=(Quantity in inventory+Quantity on Order−(Forecast Usage)). The forecast usage comprises anticipated consumption of the item derived from one or more presently scheduled clinical events. Presently scheduled events have not yet taken place and are scheduled to take place in the future. The event takes place when a clinician provides a clinical service to a patient. For example, a surgery may be scheduled to occur three days from the present time. The items scheduled for use in the surgery form part of the forecast usage for the item. The forecast usage may comprise items from multiple scheduled clinical events.
The invention relates to a Chinese patent medicine for resisting cancer, wherein guoyiwan is used for being taken orally and zhongyixiao is used for being applied externally. By combining western medicines, the Chinese patent medicine of the invention has obvious curative effect on clinically treating various types of cancers, especially can improve the immunity, can be used for auxiliary treatment and prevention of various syndromes and difficult miscellaneous diseases of patients suffering from cancer, and can early diagnose and distinguish benign and malignant tumors. Within 15 days when a patient takes the medicine, the tissues and organs of the human body tingle slightly once or twice or more times a day, and the phenomenon indicates that a tumor exists, wherein if the tumor is unheated, the tumor is benign, and if the tumor is heated, the tumor is malignant; and the cancer cells killed by the medical effect of the guoyiwan send substances for generating heat sources for heating. The guoyiwan can reduce cancer tumors and is beneficial to operations, radiotherapy and chemotherapy after being taken before the operations, radiotherapy and chemotherapy; the guoyiwan obviously improves the curative effect after being taken during the operations, radiotherapy and chemotherapy; and the guoyiwan prevents recurrence and metastasis after being taken after the operations, radiotherapy and chemotherapy. If the cancer tumors of recurrence and metastasis have unobvious effect or no effect through the radiotherapy and chemotherapy for many times and the diseases are worsened, the guoyiwan can be taken to prolong the life time and recover and cure some patients. If the cancer tumors with about one month of recurrence and metastasis have unobvious reduction through the radiotherapy and chemotherapy, the guoyiwan can be taken to completely achieve the purpose of reduction in different degrees within 15 days.
Insomnia is one of the most frequently complained sleep problems in sleep disorders, and in recent years has been regarded by the medical community as a disease that seriously affects people's lives and quality of life. The problem of perishable and perishable causes a great burden on the environment. However, banana peels actually contain many functional ingredients, such as dietary fiber, minerals, alkaloids, flavonoids, phenols, saponins, tannins and dopamine, etc. Banana peel contains more total phenols and total flavonoids than banana pulp. Studies have pointed out that banana peel extraction can inhibit the growth of fungi and bacteria. In addition, it also has antioxidant, anti-depressant, and diuretic functions. Banana peel can also improve the performance of tryptophan metabolism-related genes
Patients included in the 'stimulated' group will be stimulated at the level of the quadriceps twice a day, bilaterally and simultaneously, five days per week from Monday to Friday (Stimulator: Gymna Belgium, DUO 400). The stimulation protocol (rectified alternating current; frequency, 75 Hz; intensity, 0-80 mA; pulse duration, 350 microseconds) is the one proposed by the manufacturer for atrophy prevention. The intensity of the electrical current will be gradually increased, without exceeding 80mA or the pain threshold of the patient.
Healthy adult volunteers are assigned randomly to either a vaccine or placebo group. Injections are received either intramuscularly, intradermally, or by delivery under the skin of the volunteer's own white blood cells which have had dendritic cell reinfusion. Volunteers are vaccinated at 0, 1, 3, and 6 month time points. Volunteers are closely monitored for 1 hour after vaccination and keep a diary of symptoms for 1 week post-immunization. Volunteers undergo leukopheresis at the start of the study and after the last vaccination at Walter Reed Army Medical Center. Volunteers receive compensation benefits.
Patients aged 0-19 who have an MRI ordered clinically and have one of the following conditions: epilepsy, hydrocephalus, craniosynostosis or mild traumatic brain injury. Epilepsy, hydrocephalus and craniosynostosis patients will be both newly diagnosed and chronic. MTBI patients will be acute and chronic and defined as a glascow coma score (GCS) of 13-15.These patients will have a 10 minute MRI sequence (McDESPOT) added to their standard of care T1 and T2 scans.
Participants will be administered TPIP once per day at a starting dose of 80 micrograms (μg). Participants will be up-titrated to the highest tolerated dose for each individual participant of between 80 μg and 640 μg during the initial 3 weeks of treatment. The overall treatment period will be 16 weeks.
This invention relates to a method of inhibiting intestinal carbohydrate absorption in mammals and a dietetic preparation for use in such a method. More particularly the present invention is concerned with a method of inhibiting intestinal absorption of carbohydrates in a mammal, which method comprises orally administering a dietetic preparation to such mammal, said preparation containing α-hydroxy carboxylic acid component, whose intestinal absorption is sodium dependent, in an amount equivalent to at least 1 wt. % citric acid, so as to provide α-hydroxy carboxylic acid component in an amount which is therapeutically effective to achieve inhibition of intestinal absorption of carbohydrate. Citric acid is an example of an α-hydroxy carboxylic acid which may suitably employed.  
     The invention also encompasses a dietetic preparation in the form of an oral dosage unit of between 0.1 and 100 grams, said preparation containing between 2 and 90 wt % of α-hydroxy carboxylic acid component whose intestinal absorption is sodium dependent, between 1 and 80 wt. % of a carbohydrate absorption inhibitor selected from the group consisting of polyphenols, gymnemic acid and mixtures thereof and between 97 and 9 wt. % of pharmaceutically acceptable excipient.
BACKGROUND: The impact of the His bundle location and distance from the ablation site on ablation efficacy and complication risk remains unexplored. We determined the correlation between age, height, body mass index (BMI), and the His bundle location, and whether the distance between the His bundle and ablation target (DHIS-ABL) affects ablation safety and efficacy.
METHODS: Overall, 346 patients with atrioventricular nodal re-entrant tachycardia (AVNRT) and 96 with atrioventricular re-entrant tachycardia (AVRT) were retrospectively analyzed. The distance between the His bundle and the coronary sinus ostium (DHis-CS), the height of the His bundle (HHIS), and DHIS-ABL were measured. Electrocardiograms were obtained 3 months post-ablation to assess recurrence and complications.
RESULTS: Multiple linear regression showed that HHIS was negatively correlated with age in both groups. In AVNRT patients, DHIS-ABL was associated with age, height, and BMI; DHIS-CS was only negatively correlated with age. In AVRT patients, there was no significant correlation between the DHIS-ABL and age, height, or BMI. The recurrence rates in the AVNRT and AVRT groups were 0.9% and 8.7%, respectively. Subgroup analysis showed that patients with DHIS-ABL ≤ 10 mm had a higher recurrence rate than those with DHIS-ABL > 10 mm (p = .013). The incidence of third-degree atrioventricular block (AVB) complications was 0.2%.
CONCLUSIONS: HHIS was negatively correlated with age but not with height and BMI. The DHIS-ABL correlated with age, height, and BMI in AVNRT patients. A short DHIS-ABL led to a higher rate of supraventricular tachycardia recurrence; whether this affects AVB risk warrants further studies with larger sample sizes.
Overdosage with carbinoxamine may cause central nervous system depression or stimulation, hallucinations, convulsions, and death. Atropine-like signs and symptoms – dry mouth; fixed, dilated pupils; flushing; and gastrointestinal symptoms may also occur.

The treatment of overdosage consists of discontinuation of Carbinoxamine Maleate extended-release oral suspension and institution of symptomatic and supportive therapy. Vital signs (including respiration, pulse, blood pressure, and temperature) and EKG should be monitored.

  
Induction of vomiting is not recommended. Activated charcoal should be given and gastric lavage should be considered after ingestion of a potentially life-threatening amount of drug. In the presence of severe anticholinergic effects, physostigmine may be useful. Vasopressors may be used to treat hypotension.
The IOL-capsular complex is formed after cataract surgery and intraocular lens (IOL) implantation. Early postoperative mechanical wrapping of the anterior and posterior capsules plays a significant role in preventing IOL decentration and tilt, as well as formation of the IOL-capsular complex which reduces the incidence of posterior cataract opacity. Although up to 2-3 degree tilt and a 0.2-0.3 mm decentration are common and clinically unnoticed for any design of IOL, larger extent of tilt and decentration has a negative impact on the optical performance. IOL decentration ≥ 0.4 mm or/and IOL tilt ≥7degree were considered clinically significant cause of poor post-surgery visual quality especially for optical sophisticated IOLs. This negative impact does not affect various types of IOLs equally. Several studies indicated that AL was an independent risk factor of IOL decentration and tilt for emmetropic or moderate myopic eyes. However, there is scarce evidence on characteristics and factors associated with clinically significant IOL decentration and tilt in highly myopic eyes. For patients with high myopia, they often have a longer axial length and a larger capsule diameter, which reduces the rotational stability of the IOL and may lead to tilt, decentration and displacement of IOL. Currently, there is no literature guidance to compare the results of cataract surgery combined various types of IOLs implantation in patients with high myopia. The novel anterior segment optical coherence tomography (AS-OCT) device, CASIA2 can evaluate the IOL capsule bending and the lens position after cataract surgery. Also, CASIA2 can be used to documented the dynamic changes of IOL-capsular complex after surgery.
The study of rare diseases is important not only for the individuals affected but also for the advancement of medical knowledge and a deeper understanding of human biology and genetics. The wide repertoire of structural information now available from reliable and accurate prediction methods provides the opportunity to investigate the molecular origins of most of the rare diseases reviewed in the Orpha.net database. Thus, it has been possible to analyze the topology of the pathogenic missense variants found in the 2515 proteins involved in Mendelian rare diseases (MRDs), which form the database for our structural bioinformatics study. The amino acid substitutions responsible for MRDs showed different mutation site distributions at different three-dimensional protein depths. We then highlighted the depth-dependent effects of pathogenic variants for the 20,061 pathogenic variants that are present in our database. The results of this structural bioinformatics investigation are relevant, as they provide additional clues to mitigate the damage caused by MRD.
Reactive oxygen species are important effectors and modifiers of the acute inflammatory response, recruiting phagocytes including neutrophils to sites of tissue injury. In turn, phagocytes such as neutrophils are both consumers and producers of reactive oxygen species. Phagocytes including neutrophils generate reactive oxygen species in an oxidative burst through the activity of a multimeric phagocytic nicotinamide adenine dinucleotide phosphate oxidase complex. Mutations in the NOX2/CYBB (previously gp91phox) nicotinamide adenine dinucleotide phosphate oxidase subunit are the commonest cause of chronic granulomatous disease, a disease characterized by infection susceptibility and an inflammatory phenotype. To model chronic granulomatous disease, we made a nox2/cybb zebrafish (Danio rerio) mutant and demonstrated it to have severely impaired myeloid cell reactive oxygen species production. Reduced early survival of nox2 mutant embryos indicated an essential requirement for nox2 during early development. In nox2/cybb zebrafish mutants, the dynamics of initial neutrophil recruitment to both mild and severe surgical tailfin wounds was normal, suggesting that excessive neutrophil recruitment at the initiation of inflammation is not the primary cause of the "sterile" inflammatory phenotype of chronic granulomatous disease patients. This nox2 zebrafish mutant adds to existing in vivo models for studying reactive oxygen species function in myeloid cells including neutrophils in development and disease.
Varenicline binds with high affinity and selectivity at α 4β 2 neuronal nicotinic acetylcholine receptors. The efficacy of varenicline in smoking cessation is believed to be the result of varenicline’s activity at α 4β 2 sub-type of the nicotinic receptor where its binding produces agonist activity, while simultaneously preventing nicotine binding to these receptors. 

Electrophysiology studies in vitro and neurochemical studies in vivo have shown that varenicline binds to α 4β 2 neuronal nicotinic acetylcholine receptors and stimulates receptor-mediated activity, but at a significantly lower level than nicotine. Varenicline blocks the ability of nicotine to activate α 4β 2 receptors and thus to stimulate the central nervous mesolimbic dopamine system, believed to be the neuronal mechanism underlying reinforcement and reward experienced upon smoking. Varenicline is highly selective and binds more potently to α 4β 2 receptors than to other common nicotinic receptors (>500-fold α 3β 4, >3,500-fold α 7, >20,000-fold α 1βγδ), or to non-nicotinic receptors and transporters (>2,000-fold). Varenicline also binds with moderate affinity (Ki = 350 nM) to the 5-HT 3 receptor.
<P>PROBLEM TO BE SOLVED: To provide a solid controlled-release oral dosage formulation suppressing the release rate of an active agent and extending duration of pain relief of a patient after administering the formulation while maintaining the effect of the formulation and reducing times of administration.  <P>SOLUTION: The solid controlled-release oral dosage formulation is provided. The dosage formulation includes a core containing inactive pharmaceutical beads applied with an opioid analgesic or a salt thereof and a coating applied on the core. The coating contains an effective amount of a hydrophobic polymer to perform the controlled release of the opioid analgesic in 24 hours, the hydrophobic polymer is selected from a group consisting of plasticized acrylic polymers, plasticized ethyl cellulose and mixtures thereof. The dosage formulation provides a dissolution profile substantially unaffected in comparison of an initial solubility with a solubility after leaving the dosage formulation for 28 days under the condition of 37°C/80% relative humidity (RH).  <P>COPYRIGHT: (C)2009,JPO&INPIT